A- A A+

Adopting a child in the age of opioids (Video)

Carrie Brady had no idea the impact that opioids had on birth mothers and their children, but at age 40 she decided to start a family and open her heart to adopting a child in need. 

Find out how that decision reshaped her and her family’s life forever. (BBC, 05.04.2021, Video, 07:37)


Dr. Mary Jeanne Kreek: Mourning the Loss of a Great Addiction Pioneer 

We are profoundly saddened at the passing of Dr. Mary Jeanne Kreek last week, at age 84. A longtime NIH grantee, Mary Jeanne contributed enormously to the study of addiction, and her work has been crucial in eroding the stigma that still surrounds this disease and its treatment. She also served as a towering role model for women in science, busily breaking glass ceilings (as she put it in this oral history interview) through her tireless scientific work and leadership.

Although she made many contributions to our science, Mary Jeanne is best known for her work developing the first medication for opioid use disorder, methadone. During her medical residency in 1964, she joined the laboratory of Vincent Dole at The Rockefeller Institute for Medical Research, which was studying the neurobiology of heroin addiction with an aim to develop a medication to treat it. They identified methadone—a long-acting oral opioid analgesic—as potentially able to quell the cravings felt by patients without producing the destructive intense highs and lows produced by heroin, which both enters and leaves the brain much more quickly.

Nora D. Volkow, Director, NIDA, and George F. Koob, Director, NIAAA, 06.04.2021


Attributable fractions for substance use in relation to crime. 

Young, M. M., De Moor, C., Kent, P., Stockwell, T., Sherk, A., Zhao, J., Sorge, J. T., Farrell MacDonald, S., Weekes, J., Biggar, E., and Maloney‐Hall, B. (2021) 

Addiction, doi.org/10.1111/add.15494. 


Mary Jeanne Kreek, M.D. - Oral History Excerpts (Video)

The Rockefeller University Oral History Project, 2019, Video, 09:58


Dr. Mary Jeanne Kreek – 1937-2021

Dear colleagues, It is with great sadness that I share the news that Mary Jeanne Kreek, a beloved colleague and pioneering physician-scientist, passed away last night. Mary Jeanne was the Patrick E. and Beatrice M. Haggerty Professor and Head of the Laboratory of the Biology of Additive Diseases, as well as Senior Physician at the Rockefeller University Hospital. Mary Jeanne was a pioneer in the biology of addiction research and made seminal contributions that led to methadone’s successful use as a treatment for heroin addiction. Beyond her scientific endeavors, she was a champion for her patients, often speaking out against the societal stigma they faced. (The Rockefeller University, New York, USA, Office of the President, 28.03.2021)


Mary Jeanne Kreek, pioneer in studies of addiction, has died

Physician-scientist Mary Jeanne Kreek, the Patrick E. and Beatrice M. Haggerty Professor and a senior attending physician at The Rockefeller University, died March 27 at the age of 84. Kreek was best known for her research into the biology of drug and alcohol addiction. Her work not only yielded new treatments for these disorders, but also influenced societal attitudes toward them.

Kreek conducted landmark studies that led to the establishment of methadone as a treatment for heroin addiction. The drug, which Kreek and her colleagues developed more than 50 years ago, has been widely used in treatment programs across the globe. It has saved countless lives and allowed millions of heroin users to transition into normal lives. (The Rockefeller University, New York, USA, 29.03.2021)


Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark

Weye, Nanna et al.

The Lancet Psychiatry, Volume 8, Issue 4, 310 - 319 


Lifetime and past-month substance use and injection among street-based female sex workers in Iran. 

Roshanfekr, P., Khezri, M., Karimi, S.E. et al. 

Harm Reduct J 18, 33 (2021). doi.org/10.1186/s12954-021-00477-5



The European Liaison Office of the Research Organizations (KoWi) in cooperation with Frankfurt University of Applied Sciences and its Department of Health and Social Work (via the Institute for Addiction Research (ISFF, frankfurt-university.de/isff)) invites experienced researchers interested in the Marie Skłodowska-Curie Actions(MSCA) Postdoctoral Fellowship Call 2021 to participate in a digital Master Class on proposal writing in May 2021. Postdoctoral fellowship (PF) area great opportunity for everyone wishing to enhance their academic career. They provide exciting new learning opportunities and offer a chance of boosting your professional curriculum.


Women and Substance Use: Reading List

The theme for International Women’s Day 2021 (IWD 2021) is let’s all choose to challenge. It is everyone’s responsibility to stand up to gender inequality. For people working in the substance use prevention, treatment and recovery field, it is a reminder that we need to explore women’s experience of substance use and addiction. We need to look at the challenges that women and girls experience and the barriers they face when trying to access support. Research should be used to carefully design evidence-based interventions and services that reflect the specific needs of women. (ISSUP - International Society of Substance Use Prevention and Treatment Professionals, 08.03.2021)


Dresden. Fälschung in der Forschung: Renommierter Psychologe unter Betrugsverdacht

Hans-Ulrich Wittchen soll Daten für die wichtigste psychiatrische Studie der letzten Jahrzehnte gefälscht und sie somit wertlos gemacht haben. Hinweise auf privat verwendete Forschungsmittel werfen weitere Fragen auf. (sueddeutsche.de, 07.03.2021)


UK. Dr Nora Volkow: the SSA society lecture 2020 

In November 2020, Dr Nora Volkow delivered the SSA Society Lecture. The full lecture is now available to all non-SSA members and covers the latest research on changes in the brain that are associated with drug use and with addiction. It is a must-see lecture for everyone with an interest in addiction. (SSA – Society fort he Study of Addictions, UK, 10.03.2021)


Hazy memories in the courtroom: A review of alcohol and other drug effects on false memory and suggestibility. 

Kloft L, Monds LA, Blokland A, Ramaekers JG, Otgaar H. Hazy 

Neurosci Biobehav Rev. 2021 Feb 12;124:291-307. doi: 10.1016/j.neubiorev.2021.02.012. Epub ahead of print. PMID: 33587958.


Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. 

Siebers M, Biedermann SV, Bindila L, Lutz B, Fuss J. 

Psychoneuroendocrinology. 2021 Feb 10;126:105173. doi: 10.1016/j.psyneuen.2021.105173. Epub ahead of print. PMID: 33582575.



Addiction as a brain disease revised: why it still matters, and the need for consilience. 

Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L, Vanderschuren LJMJ. 

Neuropsychopharmacology. 2021 Feb 22. doi: 10.1038/s41386-020-00950-y. Epub ahead of print. PMID: 33619327.


Suchterkrankungen: Medizinisch-psychologische Grundlagen der Entstehung

Suchterkrankungen zählen mit mehr als 3 Millionen Betroffenen in Deutschland zu den häufigsten psychischen Störungen in der Bevölkerung. Mehr als 180.000 Menschen sterben jährlich vorzeitig an einer Alkohol- oder Tabakabhängigkeit. Die sozioökonomischen Schäden belaufen sich auf mindestens 50 Mrd. €. Es ist erstaunlich, wie wenig gesamtgesellschaftlich und gesundheitspolitisch bislang gegen Suchterkrankungen getan wird. Dass die strenge Prohibition keine taugliche Lösung darstellt, ist aufgrund des Scheiterns der US-dominierten Drogenpolitik des 20. Jahrhunderts schon lange klar (siehe hierzu auch „Deutsche Drogenpolitik im Dornröschenschlaf?“). Aber es fehlen nach wie vor smarte Politiklösungen gegen übermäßigen Substanzkonsum und Sucht, vor allem auf den Ebenen Prävention und Therapie. Alles in allem Grund genug, mehr zu den Entstehungsursachen und Hintergründen der meist im Verborgenen und mit starken Schamgefühlen ablaufenden Suchterkrankungen zu erfahren. (Michael Klein in: addiction.de, 29.01.2021)


The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder. 

Heil J, Zajic S, Albertson E, Brangan A, Jones I, Roberts W, Sabia M, Bodofsky E, Resch A, Rafeq R, Haroz R, Buono R, Ferraro TN, Scheinfeldt L, Salzman M, Baston K. 

BMC Med Genomics. 2021 Jan 7;14(1):16. doi: 10.1186/s12920-020-00837-3. PMID: 33413350; PMCID: PMC7792024.


Peer support workers as a bridge: a qualitative study exploring the role of peer support workers in the care of people who use drugs during and after hospitalization. 

Lennox, R., Lamarche, L. & O’Shea, T. 

Harm Reduct J 18, 19 (2021). doi.org/10.1186/s12954-021-00467-7


Where is the Family in Young Adult Substance Use Treatment? The Case for Systemic Family Therapy for Young Adults with Substance Use Disorders. 

Tambling RR, Russell B, D'Aniello C. 

Int J Ment Health Addict. 2021 Jan 4:1-12. doi: 10.1007/s11469-020-00471-1. Epub ahead of print. PMID: 33424512; PMCID: PMC7781401.


Grandfamilies and the Opioid Epidemic: A Systemic Perspective and Future Priorities. 

Dolbin-MacNab ML, O'Connell LM. 

Clin Child Fam Psychol Rev. 2021 Jan 25:1–17. doi: 10.1007/s10567-021-00343-7. Epub ahead of print. PMID: 33491118; PMCID: PMC7829093.


Information technology and addiction science: promises and challenges. 

Bertholet N, Cunningham JA.

Addict Sci Clin Pract. 2021 Jan 26;16(1):7. doi: 10.1186/s13722-021-00216-y. PMID: 33499925; PMCID: PMC7836206.


Cocaine, cannabis or ecstasy – whatever your drug, it has an impact on the planet

Human costs of using drugs are well-known – but the environmental impact is one of the best-kept secrets. (The Independent, UK, 13.02.2021)


Coping Strategies and Complicated Grief in a Substance Use Disorder Sample. 

Caparrós B, Masferrer L. 

Front Psychol. 2021 Jan 15;11:624065. doi: 10.3389/fpsyg.2020.624065. PMID: 33536987; PMCID: PMC7848780.


Long-Term Effects of Mind-Body Exercises on the Physical Fitness and Quality of Life of Individuals With Substance Use Disorder-A Randomized Trial.

Zhu D, Jiang M, Xu D, Schöllhorn WI. 

Front Psychiatry. 2020 Dec 18;11:528373. doi: 10.3389/fpsyt.2020.528373. PMID: 33391039; PMCID: PMC7775308.


Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry - A European Survey. 

Orsolini L, Rojnić Palavra I, Papanti GD, Potočan M, Quattrone D, Martens M, Sklenářová S, Levola J, Grichy L, Naughton S, Grinevičiene IK, Kuiters JP, Gondek TM, Panfil AL, Borovcanin MM, San Roman Uria A, Biskup E, Sönmez Güngör E, Casanova Dias M, Tomori S, Banjac V, Marinova-Djambazova P, Pinto da Costa M. 

Front Psychiatry. 2021 Jan 8;11:585607. doi: 10.3389/fpsyt.2020.585607. PMID: 33488419; PMCID: PMC7820719.


Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults. 

Hughto JMW, Quinn EK, Dunbar MS, Rose AJ, Shireman TI, Jasuja GK. 

JAMA Netw Open. 2021 Feb 1;4(2):e2036512. doi: 10.1001/jamanetworkopen.2020.36512. PMID: 33538824.


Potassium Channels and Their Potential Roles in Substance Use Disorders. 

McCoy MT, Jayanthi S, Cadet JL. 

Int J Mol Sci. 2021 Jan 27;22(3):1249. doi: 10.3390/ijms22031249. PMID: 33513859; PMCID: PMC7865894.


Association between poverty exposure during childhood and adolescence, and drug use disorders and drug-related crimes later in life. 

Manhica H, Straatmann VS, Lundin A, Agardh E, Danielsson AK.

Addiction. 2020 Nov 16. doi: 10.1111/add.15336. Epub ahead of print. PMID: 33197093.


Der Deutsche Kerndatensatz zur Dokumentation im Bereich der Suchtkrankenhilfe (KDS 3.0)

Die einheitlichen Dokumentationsstandards sind im Deutschen Kerndatensatz zur Dokumentation im Bereich der Suchtkrankenhilfe definiert. Das Erhebungsinstrument erschien in seiner ersten Version in 1998/1999. Es wurde seitdem mehrfach weiterentwickelt. Seit Januar 2017 wird der Kerndatensatz in seiner aktuellen Version KDS 3.0 angewandt. Seit Inkrafttreten gingen fortlaufend Rückmeldungen und Fragestellungen bei der DHS und dem IFT ein, die im Fachausschuss Statistik der DHS bearbeitet werden.

Wie schon in den zurückliegenden Jahren, gibt es auch zum Jahreswechsel 2020/2021 eine überarbeitete Version des KDS 3.0. Änderungen zur Ursprungsversion betreffen ausschließlich Erläuterungen und Definitionen im Manual. Die Fragebögen selbst bleiben unverändert.

Aufgrund der Rückmeldungen wurden, wie dies bereits in der früheren Version des KDS der Fall gewesen war, aktuelle inhaltliche Ergänzungen und Anpassungen in den Erläuterungen zur Itemliste des KDS 3.0 vorgenommen. An der Itemliste selbst wurden, bis auf redaktionelle Anpassungen, keine Änderungen vorgenommen.

Den KDS 3.0 mit aktuellen inhaltlichen Änderungen (gültig ab 01.01.2021) und eine detaillierte Änderungsdokumentation finden Sie unter folgenden Links:


Beratungshandbuch: Geistige Behinderung und Substanzkonsum

Grundlagen der Beratungsarbeit mit Menschen mit geistiger Beeinträchtigung und problematischem Substanzkonsum 

Hrsg: aktion:beratung, Jugendberatung und Jugendhilfe e.V., 2020